Observational studyJournal of neuro-oncology2026
Pubertal development and hormonal modulation in pediatric low-grade gliomas: a retrospective cohort study.
Observational study in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric low-grade gliomas (pLGGs) are the most common brain tumors in children. While overall survival is excellent, tumor progression remains frequent, especially in surgically challenging locations. Puberty brings profound hormonal changes, and growing evidence suggests that sex hormones may influence glioma biology. The impact of pubertal development, including central precocious puberty (CPP), on tumor behavior is not well understood.
methodsWe performed a retrospective study of 301 children with histologically confirmed pLGGs treated at a single tertiary center from 2015 to 2025. Data collected included clinical, radiological, endocrine, histopathological, and molecular information. Pubertal status was assessed using Tanner staging, and CPP was defined by standard clinical and hormonal criteria. Progression-free survival (PFS) was analyzed according to pubertal stage and, in patients with CPP, by treatment with gonadotropin-releasing hormone (GnRH) analogues. Kaplan–Meier curves and log-rank tests were used for survival analysis.
resultsAdvanced pubertal development (Tanner stage > 3) was observed in 112 patients (37%), and 18 patients (6%) met criteria for CPP. Nearly all children with CPP had tumors involving the diencephalic or hypothalamic–optic pathway. Among patients with CPP, those treated with GnRH analogues (n = 13) had significantly longer PFS than untreated patients (n = 5) (p = 0.00038), with 60-month PFS of 78% versus 25%. Tumor progression after stopping GnRH therapy often coincided with pubertal reactivation. Compared with age-matched children without CPP, GnRH therapy showed a trend toward longer PFS, though not statistically significant (p = 0.10).
conclusionsPubertal development and CPP are strongly associated with hypothalamic–optic pathway pLGGs and may influence tumor behavior in a subset of patients. In children with CPP, hormonal suppression with GnRH analogues was associated with prolonged PFS, supporting a potential modulatory role of endocrine signaling in pLGGs. These findings underscore the importance of systematic monitoring of pubertal development and warrant prospective studies to clarify the role of endocrine modulation within multimodal treatment strategies for pediatric low-grade glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.